These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9578186)

  • 1. Concentrations and effects of buspirone are considerably reduced by rifampicin.
    Lamberg TS; Kivistö KT; Neuvonen PJ
    Br J Clin Pharmacol; 1998 Apr; 45(4):381-5. PubMed ID: 9578186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations and effects of zopiclone are greatly reduced by rifampicin.
    Villikka K; Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Br J Clin Pharmacol; 1997 May; 43(5):471-4. PubMed ID: 9159561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone.
    Kivistö KT; Lamberg TS; Neuvonen PJ
    Pharmacol Toxicol; 1999 Feb; 84(2):94-7. PubMed ID: 10068153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
    Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J
    Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triazolam is ineffective in patients taking rifampin.
    Villikka K; Kivistö KT; Backman JT; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Jan; 61(1):8-14. PubMed ID: 9024169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
    Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):592-7. PubMed ID: 11180018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
    Deng S; Chen XP; Cao D; Yin T; Dai ZY; Luo J; Tang L; Li YJ
    Clin Ther; 2009 Jun; 31(6):1256-63. PubMed ID: 19695392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin reduces plasma concentrations and effects of zolpidem.
    Villikka K; Kivistö KT; Luurila H; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Dec; 62(6):629-34. PubMed ID: 9433391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampicin reduces plasma concentrations of celiprolol.
    Lilja JJ; Niemi M; Neuvonen PJ
    Eur J Clin Pharmacol; 2004 Jan; 59(11):819-24. PubMed ID: 14614579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M; Kivistö KT; Backman JT; Neuvonen PJ
    Br J Clin Pharmacol; 2000 Dec; 50(6):591-5. PubMed ID: 11136298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
    Lamberg TS; Kivistö KT; Laitila J; Mårtensson K; Neuvonen PJ
    Eur J Clin Pharmacol; 1998; 54(9-10):761-6. PubMed ID: 9923581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
    Br J Clin Pharmacol; 2003 Oct; 56(4):427-32. PubMed ID: 12968988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
    Mahmood I; Sahajwalla C
    Clin Pharmacokinet; 1999 Apr; 36(4):277-87. PubMed ID: 10320950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
    Lamberg TS; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jun; 63(6):640-5. PubMed ID: 9663178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampin decreases the plasma concentrations and effects of repaglinide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2000 Nov; 68(5):495-500. PubMed ID: 11103752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
    Park JY; Kim KA; Park PW; Park CW; Shin JG
    Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Jun; 69(6):400-6. PubMed ID: 11406737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
    Villikka K; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.